Fig. 1From: Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)Effect of benralizumab on FEV1 pre-BD-L (A), FEV1 pre-BD-% (B), FEV1 post-BD-L (C), FEV1 post-BD-% (D), ACT score (E), and miniAQLQ score (F). ACT Asthma Control Test, AQLQ Asthma Quality of Life Questionnaire, BD bronchodilator, FEV1 forced expiratory volume in 1 sBack to article page